New research challenges four-decades old obesity theory as to why and how body composition varies in young children before BMI continuously increases from age 6 years – ‘the adiposity rebound’
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-May-2026 17:16 ET (23-May-2026 21:16 GMT/UTC)
*Note – this is an early press release from the European Congress on Obesity in Istanbul, Turkey, 12-15 May. Please credit the congress when using this research*
In new research to be presented at this year’s European Congress on Obesity in Istanbul, Turkey (12-15 May) and published in The Journal of Nutrition, a 42-year old theory as to why children’s body mass index (BMI) decreases post-infancy before then rising continuously from age six years –‘the adiposity rebound’ is refuted using new analyses – rather than decreasing body fat, the real reason is proposed as increasing muscle mass. The study is by Professor Andrew Agbaje, physician and associate professor of clinical epidemiology and child health at the University of Eastern Finland, Kuopio, Finland.
The Biophysics Collaborative Access Team (BioCAT)—led by Illinois Institute of Technology faculty Thomas Irving, Professor of Biology; Weikang Ma, Professor of Biology; and Jesse Hopkins, Professor of Physics—has received the first installment of $2.6 million of a renewal award from the National Institute of General Medical Sciences of the National Institutes of Health to continue operating the BioCAT beamline at Sector 18-ID at the Advanced Photon Source at Argonne National Laboratory for the next five years.
MIT chemists have found that changing the composition of the cell membrane can alter the function of EGFR, a cell receptor that promotes proliferation and is often overactive in cancer cells.
The International Osteoporosis Foundation (IOF) has presented the prestigious IOF President’s Award to Dr Thierry Chevalley, Associate Professor at the Faculty of Medicine, University of Geneva, Switzerland. The IOF President’s Award recognises individuals who have made a significant and longstanding contribution to advancing the work of the Foundation and its mission to improve bone, muscle and joint health worldwide.
According to a study from MIT, NDMA, a carcinogen that has been found in some drugs and drinking water contaminated by chemical plants, may have a much more severe impact on children than adults.
People who take gabapentinoids, a medication prescribed increasingly frequently worldwide, particularly for chronic pain, face a much greater risk of drug poisoning if they are also taking another medication, finds a new study by University College London (UCL) researchers.
In a Policy Forum, Nizan Packin and Sharon Rabinovitz highlight the social, political, and economic risks of rapidly growing commercial prediction market (PM) platforms, such as Polymarket and Kalshi, and call for informed regulatory action. “The window for precautionary action is closing: Each week of billion-dollar PM activity, integrated into core information infrastructure without oversight comparable to that of regulated gambling, prolongs a large uncontrolled experiment on users,” write the authors. For many years, economists and computer scientists praised PMs as refined tools of collective intelligence, particularly within academic and institutional settings where they were used to generate accurate forecasts. However, a 2024 U.S. court decision permitting event-based political contracts on commercial platforms marked a turning point, accelerating the rise of large-scale, gamified markets designed for mass participation. Unlike their research-focused predecessors, these modern platforms often prioritize user engagement and profit, and by late 2025, PMs were handling more than $2 billion in transactions each week, with major events attracting wagers totaling in the hundreds of millions. According to the authors, these rapidly growing platforms raise growing concerns, including the potential for democratic manipulation, the incorporation of gambling-like mechanics, and risks to public health stemming from addictive design features.
Here, Packin and Rabinovitz discuss these concerns in detail and highlight the need for evidence-based regulatory attention. “This public health risk flourishes through systematic regulatory failure,” write the authors. “PM platforms function as ‘regulatory entrepreneurs,’ designing products to leverage legal ambiguities between gambling and financial law.” The authors note that commercial PMs can undermine democratic integrity by enabling manipulation, unequal participation, and distorted political signals. Foreign actors may legally trade on election outcomes, while thinly traded markets allow relatively small bets to shift probabilities and create misleading impressions of consensus, influencing voters, media narratives, and campaign dynamics. Weak oversight also enables insider trading risks tied to sensitive government information, which creates the ability to profit from real-world events and may even create incentives to influence the outcomes themselves. Moreover, these platforms increasingly resemble gambling systems, despite being framed as tools for forecasting, which may drive broader social and economic risks for those who use them, particularly individuals with addictive tendencies. According to Packin and Rabinovitz, PMs now occupy a pivotal juncture; they could remain valuable tools for informed decision-making if responsibly governed – or, if unchecked, they could become sources of behavioral and democratic harm. The scientific community, having contributed to their development, bears a responsibility to guide their ethical boundaries, advocate for evidence-based regulation, and ensure that innovation does not outpace accountability.
For reporters interested in topics of research integrity, author Sharon Rabinovitz notes, “One of the most underacknowledged integrity issues in addiction science is structural: stigma and implicit moral judgment constrain funding for the very research needed to ground policy and regulation in evidence. This is especially acute for behavioral addictions, where powerful financial interests consistently outpace the science and actively shape the regulatory landscape. Gambling, despite its well-documented public health impact, remains chronically under-researched relative to its regulatory urgency; trading platforms and prediction markets present an even more pressing gap, aggressively normalized yet almost entirely unexamined for addiction liability. Without greater public investment in independent research, regulation will continue to lag behind industry, repeating the mistakes of sectors that shaped the evidence base in their own favor before oversight could catch up.”
Podcast: A segment of Science's weekly podcast with Nizan Packin, related to this research, will be available on the Science.org podcast landing page [http://www.science.org/podcasts] after the embargo lifts. Reporters are free to make use of the segments for broadcast purposes and/or quote from them – with appropriate attribution (i.e., cite "Science podcast"). Please note that the file itself should not be posted to any other Web site.